Page 420 - Read Online

Shamliyan et al. Vessel Plus 2020;4:35 I http://dx.doi.org/10.20517/2574-1209.2020.34 Page 11 of 13

SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis. Can J Cardiol 2020;36:159-69.
30. Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. London: The Cochrane
Collaboration; 2011. Available from: https://training.cochrane.org/handbook/current. [Last accessed on 16 Nov 2020]
31. Slutsky J, Atkins D, Chang S, Sharp BA. AHRQ series paper 1: comparing medical interventions: AHRQ and the effective health-care
program. J Clin Epidemiol 2010;63:481-3.
32. Polisena J, Garritty C, Kamel C, Stevens A, Abou-Setta AM. Rapid review programs to support health care and policy decision making: a
descriptive analysis of processes and methods. Syst Rev 2015;4:1-7.
33. Writing Committee M, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the
American college of cardiology foundation/American heart association task force on practice guidelines. Circulation 2013;128:e240-327.
34. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the
task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with
the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37:2129-200.
35. Chow B, Rabkin SW. The relationship between arterial stiffness and heart failure with preserved ejection fraction: a systemic meta-
analysis. Heart Fail Rev 2015;20:291-303.
36. Machino-Ohtsuka T, Seo Y, Ishizu T, et al. Clinical utility of the 2016 ASE/EACVI recommendations for the evaluation of left ventricular
diastolic function in the stratification of post-discharge prognosis in patients with acute heart failure. Eur heart J Cardiovasc Imaging
2019;20:1129-37.
37. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by
echocardiography: an update from the American society of echocardiography and the European association of cardiovascular imaging. J
Am Soc Echocardiogr 2016;29:277-314.
38. Lindman BR, Davila-Roman VG, Mann DL, et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial
ancillary study. J Am Coll Cardiol 2014;64:541-9.
39. Greene SJ, Mentz RJ, Fiuzat M, et al. Reassessing the role of surrogate end points in drug development for heart failure. Circulation
2018;138:1039-53.
40. Lekavich CL, Barksdale DJ, Neelon V, Wu JR. Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review.
Heart Fail Rev 2015;20:643-53.
41. Zinman B, Inzucchi SE, Lachin JM, et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled
cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). Cardiovasc Diabetol 2014;13:102.
42. Wiviott SD, Raz I, Bonaca MP, et al. The design and rationale for the dapagliflozin effect on cardiovascular events (DECLARE)-TIMI 58
Trial. Am Heart J 2018;200:83-9.
43. Ridderstrale M, Svaerd R, Zeller C, Kim G, Woerle HJ, Broedl UC. Rationale, design and baseline characteristics of a 4-year (208-week)
phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus
with insufficient glycemic control. Cardiovasc Diabetol 2013;12:129.
44. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment
Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J 2013;166:217-23.e11.
45. Abraham WT, Ponikowski P, Brueckmann M, et al. Rationale and design of the EMPERIAL-preserved and EMPERIAL-reduced trials of
empagliflozin in patients with chronic heart failure. Eur J Heart Fail 2019;21:932-42.
46. Fu R, Gartlehner G, Grant M, et al. Conducting quantitative synthesis when comparing medical interventions: AHRQ and the effective
health care program. J Clin Epidemiol 2011;64:1187-97.
47. Levine M, Ensom MH. Post hoc power analysis: an idea whose time has passed? Pharmacotherapy 2001;21:405-9.
48. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when
interpreting results. Ann Intern Med 1994;121:200-6.
49. Yuan KH, Maxwell S. On the post hoc power in testing mean differences. J Educ Behav Stat 2005;30:141-67.
50. Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ
Publication No 10(14)-EHC063-EF. 2014. Rockville, MD. Available from: https://effectivehealthcare.ahrq.gov/index.cfm/search-for-
guides-reviews-and-reports/?pageaction=displayproduct&productid=318. [Last accessed on 16 Nov 2020]
51. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol
2011;64:1283-93.
52. Viswanathan M, Berkman ND, Dryden DM, Hartling L. Assessing risk of bias and confounding in observational studies of interventions
or exposures: further development of the RTI item bank. Rockville (MD): Agency for Healthcare Research and Quality (US); 2013.
53. Higgins JP, Altman DG, Gotzsche PC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ
2011;343:d5928.
54. Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ
2016;355.
55. Grading of Recommendations Assessment Development and Evaluation (GRADE) Workgin Group. GRADE Handbook. Available from:
http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html#h.fueh5iz0cor4. [Last accessed on 16 Nov
2020]
56. Guyatt GH, Oxman AD, Sultan S, et al. GRADE guidelines: 9. Rating up the quality of evidence. J Clin Epidemiol 2011;64:1311-6.
57. Figtree GA, Radholm K, Barrett TD, et al. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced
ejection fraction in type 2 diabetes mellitus. Circulation 2019;139:2591-3.